Меню
Набор скоро начнётся NCT07208370

Outcomes of Gillian Barrie Syn

Без фазы С лечением Outcome of Gillian Barrie

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: clinical assessment.
Кому может быть актуально
Состояния в реестре: Outcome of Gillian Barrie. Базовые параметры: 1 мес. — 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Египет
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Outcome Predictors of Gillian Barrie Syndrome In Pediatrics

Обзор

This study analyze clinical and biological factors influencing disease course and outcome. Some research identified factors like disease severity, sensory symptoms, and autonomic instability as indicators of poor outcome. Ongoing research aims to develop accurate predictive models for improved treatment and care.

Подробное описание

Guillain-Barré Syndrome (GBS) is the most common cause of acute flaccid paralysis in children worldwide, often presenting with progressive weakness, areflexia, and varying degrees of autonomic and cranial nerve involvement. It is an immune-mediated disorder, commonly triggered by preceding infections such as Campylobacter jejuni, cytomegalovirus, or Epstein-Barr virus. Pediatric patients generally have a better prognosis than adults, yet a significant proportion still suffer from residual weakness or prolonged recovery. Understanding early predictors of outcome is essential for optimizing treatment and counseling families.\[1\]\[2\] Several clinical and laboratory factors have been identified as potential predictors of poor outcomes in pediatric GBS. These include rapid progression to peak weakness, requirement of mechanical ventilation, presence of cranial nerve involvement (especially bulbar palsy), autonomic dysfunction, and the axonal subtypes of GBS on nerve conduction studies. Early identification of such factors allows for more aggressive supportive care and closer monitoring.\[3\]\[4\]\[5\] Electrophysiological classification also plays a vital role in predicting outcomes. Children with acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN) tend to have a slower and less complete recovery compared to those with acute inflammatory demyelinating polyneuropathy (AIDP). Furthermore, delayed initiation of immunotherapy such as intravenous immunoglobulin (IVIG) or plasma exchange may be associated with poorer prognosis.\[6\]\[7\] Biomarkers like elevated cerebrospinal fluid (CSF) protein without pleocytosis (albuminocytologic dissociation) are typical in GBS but do not necessarily predict outcome. However, higher CSF protein levels in the early phase may correlate with more severe disease. Some recent studies have also suggested that MRI enhancement of spinal nerve roots may be associated with disease severity, although its prognostic value remains under investigation.\[8\]\[9\] In conclusion, recognizing early outcome predictors in pediatric GBS is crucial for timely intervention, resource allocation, and family support. Although many children recover fully, identifying those at risk for complications can improve both short- and long-term care strategies.\[2\]\[3\]\[10\]

Вмешательства

  • Другое clinical assessment
    standraized clinical evaluation to assess disease sevirity and progration

Первичные конечные точки

  • Proportion of Pediatric Patients with Guillain-Barré Syndrome Achieving Full Recovery within 3 Months [Срок оценки: first 3 months after diagnosis]

Критерии участия

Критерии включения

  • All Pediatric patients (1 month to 18 years old) admitted with acute flaccid ascending paralysis and diagnosed as GBS.

Consent obtained from parents or legal guardians for participation and follow-up.

Критерии исключения

  • Children with pre-existing neuromuscular disorders. Patients with incomplete medical records or those lost to follow-up. Cases diagnosed as chronic inflammatory demyelinating polyneuropathy (CIDP).

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Диагностика

Центры проведения

Египет · 1 центр
  • Assuit University Hospital — Asyut

Публикации

  • Kalita J, Kumar M, Misra UK. Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barre syndrome in India. Muscle Nerve. 2018 May;57(5):761-765. doi: 10.1002/mus.25992. Epub 2017 Nov 7. PMID 29053890
  • Koul RL, Alfutaisi A. Prospective study of children with Guillain-Barre syndrome. Indian J Pediatr. 2008 Aug;75(8):787-90. doi: 10.1007/s12098-008-0099-1. Epub 2008 Jun 25. PMID 18581067
  • Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):711-8. doi: 10.1136/jnnp-2011-301882. Epub 2012 May 7. PMID 22566597
  • Korinthenberg R. Acute polyradiculoneuritis: Guillain-Barre syndrome. Handb Clin Neurol. 2013;112:1157-62. doi: 10.1016/B978-0-444-52910-7.00036-2. PMID 23622324
  • Shahrizaila N, Yuki N. Antiganglioside antibodies in Guillain-Barre syndrome and its related conditions. Expert Rev Neurother. 2011 Sep;11(9):1305-13. doi: 10.1586/ern.11.114. PMID 21864076

Идентификаторы

NCT: NCT07208370 · Outcomes of Gillian barrie Syn

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗